Follow on Google News News By Tag Industry News Country(s) Industry News
Follow on Google News | New publication focuses on SENSITEST® canine Lymphoma Blood TestBy: Avacta Animal Health Lymphoma is one of the most common malignancies affecting dogs, accounting for around 20 % of all canine tumours and with an estimated annual incidence of 25 per 100,000 dogs. While lymphoma responds well to chemotherapy, the relapse rate is, unfortunately, very high, requiring close monitoring during and after therapy. Until now, monitoring for disease recurrence has been achieved by palpation of peripheral lymph nodes, which occur when relapse is well underway. The paper reports a study of 57 dogs suffering from lymphoma, comparing assessment by palpation and cytology with the cLBT, a novel biomarker-based assay using serum biochemical tests for haptoglobin and C-reactive protein. The cLBT compared well with the veterinarians’ 1 I. Alexandrakis, R. Tuli, S. C. Ractliffe, S. W. Tappin, R. D. Foale, A. Roos and K. J. Slater. Utility of a multiple serum biomarker test to monitor remission status and relapse in dogs with lymphoma undergoing treatment with chemotherapy. Veterinary and Comparative Oncology. Article first published online: 15 OCT 2014 | DOI: 10.1111/vco.12123. For more information, visit www.avactaanimalhealth.com End
Account Email Address Disclaimer Report Abuse
|
|